I-Mab reports results for the quarter ended March 31 - Earnings Summary

• I-Mab IMAB.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of two analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -7 cents to -6 cents per share.

• Reported revenue was zero​; analysts expected zero.

• I-Mab's reported EPS for the quarter was a loss of 4 cents​.

• The company reported a quarterly loss of $3.15 million.

• I-Mab shares had risen by 7.1% this quarter and gained 3.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 40.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for I-Mab is $5.50

This summary was machine generated from LSEG data May 15 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)